Effects of Fingolimod on Heart Rhythm and Heart Rate Variability in Patients With Multiple Sclerosis
Condition: Multiple Sclerosis Intervention: Drug: Gilenya®; Novartis Pharmaceuticals Corporation Sponsor: Universitätsklinikum Hamburg-Eppendorf Recruiting - verified July 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials